12:00 AM
Jun 18, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Long Acting rFactor lX: Completed Phase II/III enrollment

Biogen Idec said at its analyst day that it completed enrollment in the open-label, international, pivotal Phase II/III B-LONG trial evaluating a low- and high-dose regimen of IV rFIXFc in about 129 previously-treated hemophilia B patients. The study...

Read the full 168 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >